ABVC Biopharma Inc (ABVC) Stock Analysis

AI analysis of ABVC Biopharma Inc (ABVC)

Hold

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.

Valuation Metrics

The current forward P/E ratio for ABVC Biopharma Inc (ABVC) is 0.00, compared to its 5-year average forward P/E of -1.92.

Forward P/E

Fair

5Y Average P/E

-1.92

Current P/E

0.00

Overvalued

1.06

Undervalued

-4.90

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Fair

5Y Average P/S

116.68

Current P/S

0.00

Overvalued

431.38

Undervalued

-198.03

Alphio AI Price Scenarios for ABVC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ABVC

$3.35

Scenario price

B

Base

Base · 50%ABVC

$3.17

Scenario price

B

Bear

Bear · 25%ABVC

$2.76

Scenario price

ABVC FAQ — answered by Alphio AI

ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.